Intellia Therapeutics Revenue and Competitors

Boston, MA USA

Location

$775M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Intellia Therapeutics's estimated annual revenue is currently $86.8M per year.(i)
  • Intellia Therapeutics received $150.0M in venture funding in November 2017.
  • Intellia Therapeutics's estimated revenue per employee is $130,135
  • Intellia Therapeutics's total funding is $775M.

Employee Data

  • Intellia Therapeutics has 667 Employees.(i)
  • Intellia Therapeutics grew their employee count by 10% last year.

Intellia Therapeutics's People

NameTitleEmail/Phone
1
President and CEO, Member Board DirectorsReveal Email/Phone
2
EVP and Chief Business OfficerReveal Email/Phone
3
EVP, Chief Medical OfficerReveal Email/Phone
4
Executive Assistant to the Chief Financial OfficerReveal Email/Phone
5
Chief Scientific OfficerReveal Email/Phone
6
Chief Technical OfficerReveal Email/Phone
7
Executive Assistant to the Chief Business OfficerReveal Email/Phone
8
CFOReveal Email/Phone
9
VP and Head, Clinical PharmacologyReveal Email/Phone
10
SVP, Investor Relations and Corporate CommunicationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Intellia Therapeutics?

Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology's attributes high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability and accelerate the advancement of curative products into the clinic. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/ .

keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power

$775M

Total Funding

667

Number of Employees

$86.8M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Intellia Therapeutics News

2022-04-19 - Intellia Therapeutics (NASDAQ:NTLA) Now Covered by Credit ...

Cowen began coverage on Intellia Therapeutics in a research report on Monday, January 31st. They set an “outperform” rating on the stock.

2022-04-19 - Brokerages Expect Intellia Therapeutics, Inc. (NASDAQ:NTLA ...

According to Zacks, analysts expect that Intellia Therapeutics will report full year earnings of ($4.36) per share for the current year, with...

2022-04-17 - Should You Hold Intellia Therapeutics Inc (NTLA) in Biotechnology Industry?

Should You Hold Intellia Therapeutics Inc (NTLA) in Biotechnology Industry? Friday, April 22, 2022 02:03 PM | InvestorsObserver Analysts. Should You Hold...

2021-07-05 - Intellia Therapeutics : Announces Closing of $690 Million Public Offering of Common Stock

CAMBRIDGE, Mass. - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced the closing of an underwritten public offering of 4,758,620 shares of its com ...

2021-07-02 - Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock

CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the closing of an underwritten public ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$86.4M66734%$2B
#2
$171.4M6795%N/A
#3
$244.2M709N/AN/A
#4
$107.2M71110%$1.1B
#5
$148.4M73128%N/A

Intellia Therapeutics Funding

DateAmountRoundLead InvestorsReference
2014-11-19$15.0MAAtlas VentureArticle
2015-09-02$70.0MBMultipleArticle
2017-11-03$150.0MUndisclosedCredit SuisseArticle